Company Overview
Immunome, Inc. operates within the healthcare sector as a biotechnology firm focused on the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company is currently developing a clinical asset comprising Varegacestat, a gamma secretase inhibitor, which represents its primary focus in oncology treatment development. The firm maintains a market capitalization of $2.26B and employs a workforce of 177 individuals to execute its strategic initiatives. With an annual revenue of $6.94M, the company's financial scale indicates a significant disparity between its valuation and its current revenue generation, suggesting that the market capitalization is driven largely by potential future value rather than existing cash flows. This valuation structure is typical for biotechnology entities where investor sentiment focuses on the pipeline's potential to transform the oncology landscape rather than immediate profitability metrics. The high price-to-sales ratio further underscores that the market assigns a substantial premium to the company's intellectual property and clinical pipeline prospects.
Financial Health
The company reported revenue of $6.94M over the trailing twelve months, while net income stands at a loss of $-212,394,000, revealing a cost structure where expenses significantly outweigh the minimal top-line revenue. The EBITDA figure is reported at $-211,647,008, indicating that the company's core operational activities before interest, taxes, depreciation, and amortization are generating substantial losses. Free cash flow is negative at $-133,619,624, which signifies that the company is consuming cash reserves to fund its operations and research activities rather than generating surplus liquidity. The gross margin is listed at 0.0%, the operating margin is -3084.8%, and the profit margin is 0.0%, collectively indicating that the company is not yet profitable and operates at a severe loss relative to its sales and operational costs. The firm holds cash of $653.48M against total debt of $3.85M, resulting in a debt-to-equity ratio of 0.61, which suggests a balance sheet that is conservatively managed with minimal leverage despite the lack of profitability. The current ratio of 14.69 indicates an extremely strong short-term liquidity position, providing ample coverage for current liabilities. Return on equity is -52.1% and return on assets is -29.0%, revealing that management is currently generating negative returns on the capital invested in the company's equity and asset base.
Valuation Assessment
The trailing P/E ratio is unavailable due to losses, while the forward P/E is reported as -9.47, implying that the market expects earnings to remain negative in the near term. The price-to-book ratio stands at 3.57, indicating that the market values the company at a premium of more than three times its book value, reflecting confidence in the underlying assets and pipeline. The price-to-sales ratio is exceptionally high at 326.15, and the EV/EBITDA is -7.63, suggesting that traditional valuation metrics are distorted by the company's lack of profitability and that investors are pricing in future growth potential. The stock has traded between a 52-week low of $5.15 and a 52-week high of $27.65, meaning the current trading price sits within this historical volatility range. The beta value is 2.19, indicating that the stock price is significantly more volatile than the broader market, with movements roughly twice as large as the market average. This high beta value reflects the speculative nature of the biotechnology sector and the specific risks associated with the company's drug development pipeline.
Growth & Income
Revenue growth year-over-year is -100.0%, while earnings growth year-over-year is unavailable due to the absence of prior period earnings data, implying that the company has not yet established a consistent revenue or earnings trajectory. The absence of positive earnings growth relative to revenue highlights the challenges the company faces in transitioning from a research-focused entity to a commercially viable business. As the company does not pay dividends, the dividend yield is unavailable and the payout ratio is 0.0%, indicating that all available earnings are retained to fund operations rather than distributed to shareholders. Consequently, the overall growth and income profile is characterized by a complete lack of current income generation and negative revenue trends, relying entirely on capital markets for funding.